No Data
Would Ascentage Pharma Group International (HKG:6855) Be Better Off With Less Debt?
Chinese Regulator Clears Ascentage Pharma's Cancer Drug for Phase Three Studies
Akeso Medical - B (06855): APG-2449 has obtained CDE approval to conduct Phase III clinical trials for the treatment of non-small cell lung cancer.
AstraZeneca Pharmaceutical - B (06855) announced that the company's original class 1 new drugs APG2449, FAK/ALK...
ASCENTAGE-B: INTERIM REPORT 2024
The concept of innovative drugs is generally rising. Akeso (09926) rose by 3.78%. Institutions point out that the investment and financing environment in the pharmaceutical industry is expected to recover rapidly.
Jingu Finance News | The concept of innovative drugs is generally rising, with Akeso (09926) up 3.78%, Zai Lab (09688) up 3.38%, Asymchem Laboratories (06855) up 3.11%, Innovent Bio (01801) up 3.02%, Sinopharm (01099) up 2.78%, Junshi Bio (01877) up 2.15%, Wuxi Bio (02269) up 1.71%, Beigene (06160) up 0.8%. CSC Securities released a research report stating that with the Federal Reserve announcing its first rate cut since March 2020, global liquidity
Hong Kong stock abnormal | Aisino Pharmaceutical-B (06855) rose more than 7%. The clinical results of Niletinib treatment of SDH-deficient gastrointestinal stromal tumors will be announced at the 2024 ESMO Annual Meeting.
As of the deadline, AHS Pharmaceutical-B (06855) rose more than 7%, rising 7.16% to HK$35.9, with a turnover of HK$50.4882 million.
No Data
No Data
